Evolving Drug Discovery: AI, Infrastructure, and the Speed of Learning
Gastroenterologists flag clinical remission and its durability as unmet needs in IBD care: survey
The Case for a New Generation of Oral Therapies in Inflammatory Bowel Disease
Designing Selective SIK2 Inhibitors for Dual Anti-Inflammatory and Pro-Repair Effect
Inflammatory bowel disease and other chronic inflammatory diseases remain challenging to treat, in part because durable benefit may require more than suppression of pro-inflammatory signaling alone. Emerging biology suggests that salt-inducible kinase 2 (SIK2) sits at a key node of innate immune activation and tissue repair, making it an attractive target for diseases such as ulcerative colitis.
Year One as CEO: What Leadership Actually Feels Like
Customized Amazon Nova models improve molecular-property prediction in drug discovery
A single, optimized LLM unifies what previously required multiple models and can serve as a reasoning partner for medical chemists.
Computation, Chemistry & Culture for Drug Discovery: Abbas Kazimi on The Long Run
Eli Lilly, AI Drug-Discovery Company Nimbus Partner on Oral Obesity Treatment
Nimbus, an artificial-intelligence drug-discovery company, says that it is eligible for upfront and near-term milestone payments totaling $55 million
Nimbus, Lilly sign deal to develop new oral obesity drug
Boston biotech Nimbus to partner with Eli Lilly on weight-loss pill in $1.3 billion deal
